United Services Automobile Association Sells 1,458 Shares of MEDNAX Inc (NYSE:MD)

United Services Automobile Association lessened its holdings in shares of MEDNAX Inc (NYSE:MD) by 5.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,895 shares of the company’s stock after selling 1,458 shares during the period. United Services Automobile Association’s holdings in MEDNAX were worth $679,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in MD. Summit Global Investments increased its stake in shares of MEDNAX by 7.7% in the 2nd quarter. Summit Global Investments now owns 26,700 shares of the company’s stock worth $674,000 after purchasing an additional 1,900 shares in the last quarter. Nuveen Asset Management LLC purchased a new stake in MEDNAX in the 2nd quarter worth $4,874,000. UBS Asset Management Americas Inc. increased its stake in MEDNAX by 1.9% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 124,281 shares of the company’s stock worth $3,136,000 after buying an additional 2,271 shares in the last quarter. Jane Street Group LLC purchased a new stake in MEDNAX in the 2nd quarter worth $282,000. Finally, D. E. Shaw & Co. Inc. increased its stake in MEDNAX by 20.7% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 3,001,827 shares of the company’s stock worth $75,736,000 after buying an additional 515,286 shares in the last quarter. Institutional investors and hedge funds own 92.26% of the company’s stock.

MD opened at $21.55 on Friday. The firm has a 50-day simple moving average of $22.08 and a two-hundred day simple moving average of $24.73. MEDNAX Inc has a 52 week low of $19.93 and a 52 week high of $46.21. The company has a market capitalization of $1.79 billion, a PE ratio of 6.86, a price-to-earnings-growth ratio of 0.82 and a beta of 0.73. The company has a quick ratio of 2.23, a current ratio of 2.23 and a debt-to-equity ratio of 0.79.

MEDNAX (NYSE:MD) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.78 by $0.11. MEDNAX had a negative net margin of 3.53% and a positive return on equity of 9.34%. The business had revenue of $868.31 million during the quarter, compared to the consensus estimate of $868.71 million. During the same quarter in the prior year, the firm earned $1.07 EPS. The business’s revenue was up .4% on a year-over-year basis. As a group, sell-side analysts expect that MEDNAX Inc will post 3.04 earnings per share for the current year.

In related news, Director Md Pascal J. Goldschmidt sold 5,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $20.81, for a total value of $104,050.00. Following the completion of the transaction, the director now owns 15,821 shares of the company’s stock, valued at approximately $329,235.01. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael Fernandez purchased 122,409 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was acquired at an average cost of $21.35 per share, with a total value of $2,613,432.15. Following the acquisition, the director now owns 350,288 shares in the company, valued at approximately $7,478,648.80. The disclosure for this purchase can be found here. 3.40% of the stock is owned by corporate insiders.

MD has been the subject of a number of analyst reports. Credit Suisse Group cut their price target on MEDNAX from $30.00 to $28.00 and set an “outperform” rating for the company in a research note on Tuesday, August 27th. Mizuho cut their price target on MEDNAX from $26.00 to $24.00 and set a “neutral” rating for the company in a research note on Friday, August 2nd. Zacks Investment Research lowered MEDNAX from a “hold” rating to a “sell” rating and set a $26.00 price target for the company. in a research note on Wednesday, July 3rd. UBS Group cut their price target on MEDNAX to $20.00 and set a “sell” rating for the company in a research note on Wednesday, July 24th. Finally, BMO Capital Markets dropped their price objective on shares of MEDNAX from $32.00 to $25.00 and set a “market perform” rating for the company in a report on Monday, August 5th. Four analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $28.30.

MEDNAX Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Featured Article: How is inflation measured?

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.